• Milestone Pharma
    Milestone Pharma
    • About Us
      • Leadership Team
      • Board of Directors
      • Careers
      • Contact Us
    • Areas of Focus
      • Paroxysmal supraventricular tachycardia (PSVT)
      • Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
    • Research & Development
      • Etripamil
      • Publications
      • Clinical Trials
      • Patient Access
    • Investors & Media
      • News & Events
      • Stock Information
      • Financial Information
      • Corporate Governance
      • Investor Resources
Milestone Pharma
Close
0
  • Milestone Pharma

Impact of Investigational, at-Home, Self-administered, Intranasal Etripamil on the Need for Additional Medical Intervention in Patients With Supraventricular Tachycardia

  • May 31, 2023
  • Publication
  • By Debbie Everidge
  • 0 Comments
0
  • Milestone Pharma

Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Presentation

  • May 26, 2023
  • Publication
  • By Debbie Everidge
  • 0 Comments
0
  • Milestone Pharma

Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Poster

  • May 26, 2023
  • Publication
  • By Debbie Everidge
  • 0 Comments

Potential New Therapeutic Option for the Treatment of SVT in Acute and Chronic Settings

  • May 4, 2023
  • Publication
  • By Debbie Everidge
  • 0 Comments

News in SVT Diagnosis and Management A. John Camm 16th April 2023 EHRA 2023

Careers | Contact Us | Privacy Policy | Consumer Health Data Privacy Policy | Terms of Use
© Milestone Pharmaceuticals USA, Inc. All Rights Reserved.
  • English: United States
    • English: Canada
    • Français (French): Canada

Our website content is tailored by geographical region to comply with local regulatory requirements. Please select which country’s site you’d like to visit.

  • English: United States
  • English: Canada
  • Français (French): Canada